Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Flunisolide
Drug ID BADD_D00920
Description Flunisolide (marketed as AeroBid, Nasalide, Nasarel) is a corticosteroid with anti-inflammatory actions. It is often prescribed as treatment for allergic rhinitis and its principle mechanism of action involves activation of glucocorticoid receptors.
Indications and Usage For the maintenance treatment of asthma as a prophylactic therapy.
Marketing Status approved; investigational
ATC Code R01AD04; R03BA03
DrugBank ID DB00180
KEGG ID D00324
MeSH ID C007734
PubChem ID 82153
TTD Drug ID D0FM2P
NDC Product Code 46439-8740; 51927-1794; 50742-317; 24208-344
UNII QK4DYS664X
Synonyms flunisolide | flunisolide anhydrous | 6alpha-fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16, 17-acetal with acetone | 6 alpha-fluorodihydroxy-16 alpha,17 alpha-isopropylidenedioxy-1,4-pregnadiene-3,20- dione | flunisolide hemihydrate | flunisolide hemihydrate, (6alpha,11beta,16alpha)-isomer | Nasarel | AeroBid | Aerospan | RS-3999 | Nasalide | flunisolide acetate | RS-1320 | RS1320 | flunisolide 21-acetate | flunisolide, (6beta,11beta,16alpha)-isomer | ratio-Flunisolide | Rhinalar | Syntaris | flunisolide HFA | flunisolide hydrofluoroalkane | Apo-Flunisolide | Inhacort
Chemical Information
Molecular Formula C24H31FO6
CAS Registry Number 3385-03-3
SMILES CC1(OC2CC3C4CC(C5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C)F)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dyspnoea02.11.05.003; 22.02.01.004--
Ear infection11.01.05.001; 04.03.01.006--Not Available
Ear pain04.03.01.003--
Eczema23.03.04.006--
Epistaxis24.07.01.005; 22.04.03.001--
Erythema multiforme23.03.01.003; 10.01.03.015--
Eye infection11.01.06.001; 06.04.05.007--
Fatigue08.01.01.002--
Feeling abnormal08.01.09.014--Not Available
Gastroenteritis11.01.07.004; 07.19.03.001--Not Available
Gastrointestinal pain07.01.05.005--
Glaucoma06.03.01.002--
Glossitis07.14.01.001--Not Available
Headache17.14.01.001--
Hyperadrenocorticism24.08.02.005; 14.11.01.009; 05.01.01.003--Not Available
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hyperkinesia17.01.02.008--Not Available
Hypersensitivity10.01.03.003--
Hypertension24.08.02.001--
Hypoaesthesia23.03.03.081; 17.02.06.023--Not Available
Hypokinesia17.01.02.009--Not Available
Increased appetite08.01.09.027; 14.03.01.003--Not Available
Infection11.01.08.002--Not Available
Injury12.01.08.004--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Intraocular pressure increased13.07.04.002--Not Available
Irritability19.04.02.013; 08.01.03.011--
Lacrimation increased06.08.02.004--
Laryngitis22.07.03.001; 11.01.13.001--
Loss of consciousness17.02.04.004--Not Available
The 2th Page    First    Pre   2 3 4    Next   Last    Total 4 Pages